BULLETIN V2025-1076
NERVGEN PHARMA CORP. ("NGEN")
BULLETIN TYPE: Prospectus-Share Offering
BULLETIN DATE: April 14, 2025
TSX Venture Tier 2 Company
Financing Type: At-the-market Prospectus Offering
Gross Proceeds: $1,639,761 in the quarter ended March 31, 2025
Offering: 564,500 Listed Shares
Offering Price: An average price of $2.91 per Listed Share
Warrant Exercise Terms: N/A
Commissions in Securities: N/A
Disclosure: Refer to the prospectus supplement dated December 19, 2024, and the Company's news release dated April 9, 2025.
_______________________________________
|
|
